The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is now more than halfway to achieving the target number of study sites.
To date, 86 of a planned 150 certified mammography clinics in the U.S., Canada and Argentina are already actively taking part in TMIST. With site enrollment in full swing, TMIST patient enrollment has nearly quadrupled in 2019 and is steadily increasing.
“We are still seeking more sites to enroll women in TMIST. We have 10 approved clinics working to begin enrollment. Another 35 have committed to joining,” the study’s principal investigator Etta Pisano, MD, and chief research officer the American College of Radiology, said.
Benefits of TMIST participation, outlined in this video, have attracted interest from non-academic, community-based women’s health services, large health systems and freestanding radiology facilities alike.
“NCI funding supports the work required, sites can still bill insurance or Medicare for the clinical work. There is even a fund to pay for screening exams for uninsured qualified US women. We anticipate that sites will continue to apply,” added Pisano.
Trial staff suggest new sites designate specific blocks of research coordinator time to accrue women to the study. Facilities can apply for a $30,000 reimbursement advance to pay for such RA time.
TMIST is the first large randomized controlled trial that seeks to identify women in which digital breast tomosynthesis (DBT) may outpace two-dimensional (2D) digital mammography at reducing advanced breast cancer development. TMIST will also create the world’s largest breast cancer biorepository.
Dr. Pisano will hold informational sessions for prospective domestic sites Dec. 3 at 2 p.m. EST and international sites Dec. 4 at 2 p.m. EST at booth W192c at the Radiological Society of North America 2019 annual meeting.
Pisano will also hold informational sessions March 11 to 15, 2020 at the European Congress of Radiology conference in Vienna, Austria and April 9, 2020 at the Global Breast Cancer Conference 2020 in Seoul, Korea.
Visit TMIST to find out how and why your practice should take part in the largest randomized controlled breast cancer screening trial in decades.
Email TMIST@acr.org with any questions you may have about TMIST.